Abivax SA (ABVX) H1 2026 Financial Results
QuoteReporter
Abivax (ABVX) Q1 2026: Significant Net Loss Increase — Disappointing
Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) reported a net loss of €165.9 million for the first half of 2026, an increase of €65.1 million or +64.5% compared to a net loss of €100.8 million in the same period last year. This substantial increase in losses is disappointing for shareholders, primarily due to escalating research and development expenses as the company prepares for the potential commercialization of its lead drug candidate, obefazimod.
Key Financial Metrics
- Total Operating Income: €2.5 million (up from €2.1 million in H1 2025)
- Total Operating Expenses: €142.8 million (up from €96.3 million in H1 2025)
- R&D Expenses: €107.9 million (up from €77.9 million)
- G&A Expenses: €30.4 million (up from €16.3 million)
- Sales and Marketing Expenses: €4.6 million (up from €1.5 million)
- Operating Loss: €140.3 million (up from €93.7 million)
- Financial Loss: €31.4 million (up from €7.1 million)
- Net Loss: €165.9 million (up from €100.8 million)
- Cash Position: €402.4 million as of June 30, 2026
- Net Proceeds from Public Offering: €767.1 million
The increase in operating expenses was driven by a significant rise in R&D costs, which accounted for 75.5% of total operating expenses. This increase was largely due to ongoing clinical trials and preparations for the potential launch of obefazimod, which is currently in Phase 3 trials for ulcerative colitis. The company also experienced a notable rise in general and administrative expenses, primarily due to increased personnel costs and consulting fees.
Cash and Debt Position
Abivax's cash, cash equivalents, and short-term investments totaled €402.4 million as of June 30, 2026. This, combined with €767.1 million in net proceeds from a public offering completed in early July, provides a cash runway projected into Q4 2029. The company has also successfully completed the repurchase of all outstanding royalty certificates for a total consideration of $90 million (approximately €76.5 million), which has materially reduced its royalty overhang and strengthened its debt-free financial position.
Dividend and Buyback Updates
There were no dividends declared or share buybacks announced during this reporting period. However, the completion of the royalty certificate repurchase is a strategic move that enhances the company's flexibility for future commercialization efforts.
Forward Guidance
Looking ahead, Abivax is preparing for a planned NDA submission for obefazimod in ulcerative colitis by the end of 2026. This submission is a critical milestone that could significantly impact the company's future revenue potential and market position.
Conclusion
In summary, while Abivax continues to make progress in its clinical programs and has a solid cash position, the substantial increase in net losses and operating expenses raises concerns for shareholders. The upcoming NDA submission for obefazimod will be a key catalyst to watch in the next quarter, as it could pave the way for future growth and recovery in shareholder value.
Income Statement / P&L
Currency: Euros (in millions)
| Statement of Income (Loss) | For the six months ended June 30, | 2025 | 2026 |
|---|---|---|---|
| Total operating income | 2.1 | 2.5 | |
| Total operating expenses | |||
| of which Research and Development costs | (77.9) | (107.9) | |
| of which Sales and Marketing costs | (1.5) | (4.6) | |
| of which General and Administrative costs | (16.3) | (30.4) | |
| Operating loss | (93.7) | (140.3) | |
| Financial gain (loss) | (7.1) | (31.4) | |
| Net loss before tax | (100.8) | (171.7) | |
| Income tax | — | 5.8 | |
| Net loss for the period | (100.8) | (165.9) |
Balance Sheet
Currency: Euros (in millions)
| Statement of Financial Position | As of | December 31, 2025 | June 30, 2026 |
|---|---|---|---|
| Non-current assets | 33.1 | 34.6 | |
| Cash and cash equivalents | 516.7 | 388.0 | |
| Other current assets1 | 34.6 | 39.6 | |
| Total Assets | 584.3 | 462.2 | |
| Borrowings, notes and derivative instruments2 | 1.9 | 1.2 | |
| Royalty Certificates | 30.2 | — | |
| Other non-current liabilities | 35.3 | 24.1 | |
| Other current liabilities | 61.7 | 70.6 | |
| Total Liabilities | 129.1 | 95.9 | |
| Total Shareholders’ Equity | 455.2 | 366.3 | |
| Total Liabilities and Shareholders’ Equity | 584.3 | 462.2 |
1 Includes certain short-term investments (terms of less than 12 months) of €14.4M, making total cash, cash equivalents and short-term investments of €402.4 million
2 Includes both current and non-current portions of borrowings, convertible loan notes, derivative instruments, and lease liabilities
(Note: No tables were omitted from this content.)
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
